Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease
Innovating the Future of Alzheimer’s Care at the center of Diagnosis
The ALZpath difference
ALZpath provides diagnostic tools and expertise in Alzheimer’s disease. We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.
Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification
A timely and accessible diagnosis
Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:
- Simple
- Accessible
- Timely
- Cost-effective
- Less invasive
pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.
ALZpath Appoints Mike Banville as CEO
Jan 27, 2025
ALZpath, Inc. has appointed Mike Banville as CEO, effective January 1. Banville brings extensive leadership experience in scaling early-stage companies across healthcare, technology, and education sectors. He aims to drive ALZpath’s mission of advancing accessible, early, and accurate Alzheimer’s diagnosis through its groundbreaking pTau217 blood-based assay.
Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
Nov 18, 2024
Bio-Techne and ALZpath have partnered to accelerate Alzheimer’s research by combining Bio-Techne’s Ella automated immunoassay platform with ALZpath’s pTau217 antibody. The collaboration enables rapid, precise detection of Alzheimer’s biomarkers from plasma samples in just 90 minutes, helping to advance research and treatment development.
Beckman Coulter Diagnostics to use ALZpath proprietary pTau antibody in Alzheimer’s diagnostic test
July 15, 2024
ALZpath announces a licensing agreement with Beckman Coulter Diagnostics to integrate its proprietary pTau217 antibody into a blood-based diagnostic for Alzheimer’s disease on Beckman Coulter’s DxI 9000 Immunoassay Analyzer. This in vitro diagnostic (IVD) test will enhance early and accurate Alzheimer’s diagnosis.
New Study in Alzheimer's & Dementia Reports Longitudinal pTau217
July 10, 2024
“Higher p-tau217 levels correlate with accelerated cognitive decline, thereby reinforcing the utility of p-tau217 as a powerful predictor of preclinical AD progression” as demonstrated in a critical new study by Dr. Du and team in the Wisconsin Registry for Alzheimer’s Prevention. This important research provides insights into longitudinal changes in plasma pTau217 and the capacity for this biomarker to predict cognitive decline.
